Research programme: cancer therapeutics - Isogenica/NanoCarrier

Drug Profile

Research programme: cancer therapeutics - Isogenica/NanoCarrier

Latest Information Update: 19 May 2008

Price : $50

At a glance

  • Originator CTT Cancer Targeting Technologies; NanoCarrier
  • Developer Isogenica; NanoCarrier
  • Class Peptides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 06 May 2008 Karyon-CTT has been acquired and merged into Isogenica
  • 01 May 2007 Preclinical development is ongoing
  • 03 Nov 2003 Preclinical trials in Cancer in Finland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top